<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04205929</url>
  </required_header>
  <id_info>
    <org_study_id>OHSU IRB 20645</org_study_id>
    <nct_id>NCT04205929</nct_id>
  </id_info>
  <brief_title>Use of Curcumin to Treat Unfavorable Bleeding Patterns in Contraceptive Implant Users</brief_title>
  <official_title>Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users: a Randomized Clinical Trial of Curcumin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan to study the effects of curcumin, the active ingredient in the spice
      turmeric, on the irregular bleeding experienced by women who use the contraceptive implant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are proposing a randomized, double blind placebo-controlled clinical trial
      over a 30-day reference period for treatment of women experiencing bothersome bleeding while
      using the etonogestrel (ENG) contraceptive implant. The primary outcome of the study will be
      the total number of amenorrhea days in a 30-day reference period. The study has a number of
      secondary outcomes (see study objectives) focused around the efficacy of oral curcumin to
      stop bleeding/spotting and for how long.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo-controlled Computer-generated randomization schema</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Total number of amenorrhea days</measure>
    <time_frame>Day 1 to Day 30</time_frame>
    <description>Total number of bleeding free days in the 30-day reference period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total number of bleeding/spotting days</measure>
    <time_frame>Day 1 to Day 30</time_frame>
    <description>Total number of days with bleeding or spotting in the 30-day reference period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of consecutive bleeding-free days</measure>
    <time_frame>Day 1 to Day 30</time_frame>
    <description>Number of consecutive days with no bleeding after beginning treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of spotting days</measure>
    <time_frame>Day 1 to Day 30</time_frame>
    <description>Total number of days with spotting in the 30-day reference period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of bleeding days</measure>
    <time_frame>Day 1 to Day 30</time_frame>
    <description>Total number of days with bleeding in the 30-day reference period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (days) to stop bleeding</measure>
    <time_frame>Day 1 to Day 30</time_frame>
    <description>Number of days for bleeding to stop after beginning treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient satisfaction with bleeding pattern as assessed by VAS</measure>
    <time_frame>Day 1 to Day 30</time_frame>
    <description>Level of patient satisfaction with bleeding pattern as measured by Visual Analog Scale (VAS). The scale ranges from 0 (lowest possible satisfaction) to 100 (highest possible satisfaction).</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of participants who intend to continue use of implant</measure>
    <time_frame>Day 30</time_frame>
    <description>Percentage of participants who are continuing implant use or anticipate implant continuation, evaluated at the end of study</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Bleeding</condition>
  <condition>Implants</condition>
  <condition>Breakthrough Bleeding</condition>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (oral) once daily for 30 days to be started following 3 consecutive days of bleeding</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Curcumin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Curcumin 600 mg (oral) once daily for 30 days to be started following 3 consecutive days of bleeding</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (oral) once daily for 30 days. Treatment to be started after 3 consecutive days of bleeding</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <description>Curcumin 600 mg (oral) once daily for 30 days. Treatment to be started after 3 consecutive days of bleeding</description>
    <arm_group_label>Curcumin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  English speaking

          -  Women 15-45 years of age

          -  Currently using the ENG implant for at least 30 days and use proven on exam (palpation
             of implant at screening visit)

          -  Willing to continue using the implant for at least 30 days from study enrollment

          -  &gt;7 days of continuous bleeding/spotting in the last 30 days, OR 2 or more episodes of
             bleeding/spotting in the last 30 days.

          -  Access to a reliable cell phone and must be willing to receive and respond to a daily
             text or email message to assess bleeding and use of study drug

          -  Negative gonorrhea/chlamydia screening performed at screening visit

        Exclusion Criteria:

          -  Postpartum within six months

          -  Post-abortion within six weeks

          -  Currently pregnant

          -  Currently breast-feeding (to be eligible, must be 4-6 weeks from cessation of
             breastfeeding)

          -  Undiagnosed abnormal uterine bleeding pre-dating placement of contraceptive implant

          -  Bleeding dyscrasia

          -  Anticoagulation use

          -  Active cervicitis

          -  Allergy to curcumin or turmeric

          -  History of venous thromboembolism

          -  Current or past breast or uterine malignancy

          -  Use of P450 pathway inducing drug

          -  Implant is due to be switched out in 2 months or less from enrollment

          -  Currently using oral contraceptives in addition to implant (to be eligible, needs to
             have a 4-6 week washout period)

          -  Prior pregnancy occurred while Nexplanon/Implanon was in place
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Women's Health Research Unit Department of OB/Gyn</last_name>
    <phone>503-494-3666</phone>
    <email>whru@ohsu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>OHSU</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison B Edelman, MD, MPH</last_name>
      <phone>503-494-5949</phone>
      <email>edelmana@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Alison B Edelman, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 16, 2019</study_first_submitted>
  <study_first_submitted_qc>December 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2019</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Alison Edelman</investigator_full_name>
    <investigator_title>Professor OB/Gyn</investigator_title>
  </responsible_party>
  <keyword>Contraceptive implant</keyword>
  <keyword>Irregular bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metrorrhagia</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

